Skip to main content

Table 2 Trial enrollment by region and country[8]

From: Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogenetics

Region Country TC (n = 243) Decitabine (n = 242)
Patients, n (%) Patients, n (%)
Eastern Europe   113 (46.5) 109 (45.0)
  Poland 47 (19.3) 41 (16.9)
  Russian Federation 29 (11.9) 28 (11.6)
  Czech Republic 23 (9.5) 24 (9.9)
  Serbia 10 (4.1) 12 (5.0)
  Hungary 3 (1.2) 4 (1.7)
  Romania 1 (0.4) 0 (0.0)
North America/ Australia   69 (28.4) 51 (21.1)
  United States 27 (11.1) 21 (8.7)
  Australia 22 (9.1) 16 (6.6)
  Canada 20 (8.2) 14 (5.8)
Western Europe   34 (14.0) 51 (21.1)
  France 24 (9.9) 31 (12.8)
  Spain 10 (4.1) 20 (8.3)
Asia   27 (11.1) 31 (12.8)
  Taiwan 27 (11.1) 31 (12.8)
  1. Percentages were calculated using the number of patients in each group as the denominator.
  2. SC, supportive care; TC, patient's choice of treatment with physician's advice.